Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review
Arun Sharma1★, S Amarnath1, Devendra Singh Kushwah2, S Ramaswamy1★ Corresponding author
- 1Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry – 605502, INDIA.
- 2Department of Pharmacology, Netaji Subash Chandra Bose Medical College & Hospital, Jabalpur – 482003, INDIA.
CORRESPONDENCE
Arun Sharma
Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry – 605502, INDIA.
Volume 7, Issue 1 · pp. 2–6 · PUBLISHED · DOI: 10.5530/jyp.2015.1.2
ABSTRACT
Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. The associated dyslipidemia adds to the lethality of type 2 diabetes mellitus and requires newer and better treatment strategies. Peroxisome proliferator activated receptor (PPAR) α and γ agonists are approved hypolipidemic and anti-diabetic agents respectively and combining them together provides a dual benefit in type 2 diabetes mellitus associated with dyslipidemia. This novel class of dual PPAR agonists are termed as “Glitazars” and in 2013, Saroglitazar, a member of this class of drugs; was approved by the Indian regulatory authority Drug Controller General of India (DCGI) for the treatment of diabetic dyslipidemia. It is the first glitazar to gain regulatory approval anywhere in the world and is also the first New Chemical Entity (NCE) to be discovered in India. This review provides an overview of this novel drug including its mechanism of action and prospective uses.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Sharma, A., Amarnath, S., Kushwah, D. S., & Ramaswamy, S. (). Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review. Journal of Young Pharmacists, 7(1), 2–6. https://doi.org/10.5530/jyp.2015.1.2